New drug combo tested for tough pancreatic cancer

NCT ID NCT02021422

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested whether adding the drug anakinra to standard chemotherapy is safe for people with metastatic pancreatic cancer. Thirteen adults with advanced disease received the combination. The main goal was to check for side effects, not to see if it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

anakinra (Kineret) plus standard chemotherapy (oxaliplatin, irinotecan, fluorouracil)

What this could lead to

If this combination proves safe, it could point toward a new treatment option for metastatic pancreatic cancer.

What could go wrong

This is a very early, small Phase 1 safety trial with only 13 participants. It cannot prove the treatment works, and side effects or lack of benefit are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Baylor Sammons Cancer Center

    Dallas, Texas, 75246, United States